FIELD: biotechnology.
SUBSTANCE: group of inventions relates to the treatment of a condition or disorder associated with B cells. A method for treating a B-cell-related condition or disorder in a subject involves administering one or more gamma secretase inhibitors to the subject and administering a therapeutic agent that binds to BCMA, selected from a group consisting of an anti-BCMA antibody or fragment thereof, a conjugate of an anti-BCMA antibody and a drug, and a chimeric antigen receptor T cell (CAR-T cell) that binds to BCMA. A method for improving the effectiveness of therapy in a subject receiving treatment with a therapeutic agent that binds to BCMA, a condition or disorder associated with B cells, is also disclosed.
EFFECT: group of inventions provides increased effectiveness of therapeutic agents directed against BCMA.
32 cl, 1 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY FOR THE TREATMENT OF BCMA-RELATED CANCER AND AUTOIMMUNE DISORDERS | 2018 |
|
RU2799762C2 |
| METHODS FOR THE TREATMENT OF COCHLEAR SYNAPTOPATHY | 2017 |
|
RU2757276C2 |
| BARRETT'S OESOPHAGUS THERAPY | 2006 |
|
RU2432163C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| COMBINATION THERAPY | 2017 |
|
RU2754507C2 |
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT | 2019 |
|
RU2794261C2 |
| IMPROVED COMPOSITIONS BASED ON T-CELLS | 2015 |
|
RU2719030C2 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| THERAPY OF INTESTINAL ADENOMA AND/OR ADENOCARCINOMA BY INHIBITING NOTCH ACTIVATION | 2005 |
|
RU2392961C2 |
